Coherus Additional Paid In Capital from 2010 to 2024
| CHRS Stock | USD 1.22 0.04 3.17% |
Additional Paid In Capital | First Reported 2010-12-31 | Previous Quarter 929.3 M | Current Value 975.7 M | Quarterly Volatility 394.4 M |
Check Coherus BioSciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Coherus BioSciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2 M, Interest Expense of 42.6 M or Selling General Administrative of 100.1 M, as well as many indicators such as Price To Sales Ratio of 1.16, Dividend Yield of 0.0 or Days Sales Outstanding of 388. Coherus financial statements analysis is a perfect complement when working with Coherus BioSciences Valuation or Volatility modules.
Coherus | Additional Paid In Capital |
Latest Coherus BioSciences' Additional Paid In Capital Growth Pattern
Below is the plot of the Additional Paid In Capital of Coherus BioSciences over the last few years. Additional Paid In Capital (or APIC) is an accounting term found on Coherus BioSciences Balance Sheet under Shareholders Equity. It is the value of the shares of the company above what they were issued it. The basic calculation is as follow: (Issue Price - Par Value) x Coherus BioSciences Shares Outstanding. Additional Paid In Capital is not affected by secondary trading of Coherus BioSciences shares and does not have any impact on the value of APIC. It is the excess amount paid by investors over the par value of a company's shares, representing the additional capital contributed by shareholders. Coherus BioSciences' Additional Paid In Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Coherus BioSciences' overall financial position and show how it may be relating to other accounts over time.
| Additional Paid In Capital | 10 Years Trend |
|
Additional Paid In Capital |
| Timeline |
Coherus Additional Paid In Capital Regression Statistics
| Arithmetic Mean | 509,246,097 | |
| Coefficient Of Variation | 77.45 | |
| Mean Deviation | 363,816,077 | |
| Median | 808,060,000 | |
| Standard Deviation | 394,390,159 | |
| Sample Variance | 155543.6T | |
| Range | 982.7M | |
| R-Value | 0.90 | |
| Mean Square Error | 30729.8T | |
| R-Squared | 0.82 | |
| Slope | 79,689,643 | |
| Total Sum of Squares | 2177610.4T |
Coherus Additional Paid In Capital History
About Coherus BioSciences Financial Statements
Coherus BioSciences shareholders use historical fundamental indicators, such as Additional Paid In Capital, to determine how well the company is positioned to perform in the future. Although Coherus BioSciences investors may analyze each financial statement separately, they are all interrelated. The changes in Coherus BioSciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Coherus BioSciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Additional Paid In Capital | 929.3 M | 975.7 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.